​

Veracyte (VCYT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

VCYT Stock Forecast

Veracyte (VCYT) stock forecast, based on 20 Wall Street analysts, predicts a 12-month average price target of $45.25, with a high of $52.00 and a low of $37.00. This represents a 9.04% increase from the last price of $41.50.

$15 $23 $31 $39 $47 $55 High: $52 Avg: $45.25 Low: $37 Last Closed Price: $41.5

VCYT Stock Rating

Veracyte stock's rating consensus is Buy, based on 20 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (65.00%), 6 Hold (30.00%), 1 Sell (5.00%), and 0 Strong Sell (0.00%).

Buy
Total 20 0 1 6 13 Strong Sell Sell Hold Buy Strong Buy

VCYT Price Target Upside V Benchmarks

TypeNameUpside
StockVeracyte9.04%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts239
Avg Price Target$47.00$43.67$43.11
Last Closing Price$41.50$41.50$41.50
Upside/Downside13.25%5.23%3.88%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
May, 261911-12
Apr, 261821-12
Mar, 261821-12
Feb, 261821-12
Jan, 261821-12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 06, 2026UBS$52.00$39.4431.85%25.30%
May 06, 2026Kyle MiksonCanaccord Genuity$42.00$32.9727.39%1.20%
Mar 05, 2026Kallum TitchmarshMorgan Stanley$37.00$34.686.69%-10.84%
Jan 05, 2026Subbu NambiGuggenheim$50.00$42.9516.41%20.48%
Dec 01, 2025Morgan Stanley$48.00$46.393.47%15.66%
Nov 05, 2025Lu LiUBS$48.00$43.649.99%15.66%
Nov 05, 2025Kyle MiksonCanaccord Genuity$43.00$36.1219.05%3.61%
Oct 20, 2025Kyle MiksonCanaccord Genuity$40.00$35.8311.64%-3.61%
Aug 08, 2025Tejas SavantMorgan Stanley$28.00$27.372.30%-32.53%
Nov 07, 2024Mike MatsonNeedham$44.00$35.8522.73%6.02%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 06, 2026UBSBuyBuyhold
Mar 05, 2026Morgan StanleyUnderweightUnderweighthold
Jan 12, 2026UBSBuyBuyhold
Jan 05, 2026GuggenheimBuyBuyhold
Nov 05, 2025UBSBuyBuyhold
Nov 05, 2025NeedhamBuyBuyhold
Nov 05, 2025Canaccord GenuityHoldHoldhold
Aug 08, 2025Morgan StanleyUnderweightUnderweighthold
Oct 15, 2024UBSBuyinitialise
Oct 10, 2024GuggenheimBuyinitialise

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-1.11$-0.51$-1.02$0.32$0.84----
Avg Forecast$-1.14$-0.61$-0.71$0.36$0.50$0.71$1.12$1.38$1.52
High Forecast$-1.14$-0.61$-0.62$0.37$0.53$0.88$1.59$1.40$1.55
Low Forecast$-1.14$-0.61$-0.77$0.35$0.48$0.54$0.65$1.35$1.49
Surprise %-2.63%-16.39%43.66%-11.11%68.00%----

Revenue Forecast

$200M $300M $400M $500M $600M $700M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$219.51M$296.54M$361.05M$445.76M$517.14M----
Avg Forecast$214.82M$291.31M$354.58M$443.91M$487.76M$540.63M$592.77M$636.08M$672.40M
High Forecast$214.82M$291.31M$354.58M$445.00M$490.33M$556.35M$592.84M$645.88M$682.76M
Low Forecast$214.82M$291.31M$354.58M$442.63M$486.23M$531.04M$592.70M$626.12M$661.88M
Surprise %2.19%1.79%1.82%0.42%6.02%----

Net Income Forecast

$-250M $-170M $-90M $-10M $70M $150M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-75.56M$-36.56M$-74.40M$24.14M$66.35M----
Avg Forecast$-170.25M$-59.07M$-74.40M$28.69M$40.22M$53.25M$73.70M$109.87M$121.46M
High Forecast$-136.20M$-47.26M$-59.52M$29.34M$42.10M$70.49M$126.78M$112.07M$123.89M
Low Forecast$-204.30M$-70.88M$-89.28M$28.03M$38.33M$42.91M$52.20M$107.63M$118.99M
Surprise %-55.62%-38.11%--15.85%64.98%----

VCYT Forecast FAQ

Is Veracyte stock a buy?

Veracyte stock has a consensus rating of Buy, based on 20 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 6 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Veracyte is a favorable investment for most analysts.

What is Veracyte's price target?

Veracyte's price target, set by 20 Wall Street analysts, averages $45.25 over the next 12 months. The price target range spans from $37 at the low end to $52 at the high end, suggesting a potential 9.04% change from the previous closing price of $41.5.

How does Veracyte stock forecast compare to its benchmarks?

Veracyte's stock forecast shows a 9.04% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Veracyte over the past three months?

  • May 2026: 8.33% Strong Buy, 75.00% Buy, 8.33% Hold, 8.33% Sell, 0% Strong Sell.
  • April 2026: 8.33% Strong Buy, 66.67% Buy, 16.67% Hold, 8.33% Sell, 0% Strong Sell.
  • March 2026: 8.33% Strong Buy, 66.67% Buy, 16.67% Hold, 8.33% Sell, 0% Strong Sell.

What is Veracyte’s EPS forecast?

Veracyte's average annual EPS forecast for its fiscal year ending in December 2026 is $0.71, marking a -15.48% decrease from the reported $0.84 in 2025. Estimates for the following years are $1.12 in 2027, $1.38 in 2028, and $1.52 in 2029.

What is Veracyte’s revenue forecast?

Veracyte's average annual revenue forecast for its fiscal year ending in December 2026 is $540.63M, reflecting a 4.54% increase from the reported $517.14M in 2025. The forecast for 2027 is $592.77M, followed by $636.08M for 2028, and $672.4M for 2029.

What is Veracyte’s net income forecast?

Veracyte's net income forecast for the fiscal year ending in December 2026 stands at $53.25M, representing a -19.75% decrease from the reported $66.35M in 2025. Projections indicate $73.7M in 2027, $109.87M in 2028, and $121.46M in 2029.